Merck: hopes for Keytruda in liver cancer
(CercleFinance.com) - Merck today announced that a phase III trial of Keytruda in Asian patients with advanced hepatocellular carcinoma (HCC) (liver cancer) previously treated with sorafenib has met its primary endpoint of overall survival (OS).
The study showed a statistically significant improvement in OS in the Keytruda regimen compared to the placebo regimen.
The company said the study also met its primary secondary endpoints of progression-free survival and objective response rate.
The results of the study will be presented at an upcoming medical meeting, Merck added.
Copyright (c) 2021 CercleFinance.com. All rights reserved.
The study showed a statistically significant improvement in OS in the Keytruda regimen compared to the placebo regimen.
The company said the study also met its primary secondary endpoints of progression-free survival and objective response rate.
The results of the study will be presented at an upcoming medical meeting, Merck added.
Copyright (c) 2021 CercleFinance.com. All rights reserved.